Telix Pharmaceuticals Limited (ASX:TLX) agreed to acquire Optimal Tracers from Northern California PET Imaging Center for AUD 1.7 million on November 14, 2022. The consideration includes a contingent payment of AUD 0.7 million based on a percentage of sales to existing customers of Optimal Tracers for a period of 24 months. Telix will fund the acquisition from operational cash flow.

Telix will have ownership of all intellectual property, physical assets and licences of Optimal Tracers.